Targeting MMP1 and its downstream signaling pathways, such as the ANXA1-FPR3 and CXCL16-CXCR6 axes, represented a promising therapeutic strategy to disrupt these tumor-promoting mechanisms and enhance anti-tumor immunity. This evidence concerns the gene FPR3 and neoplasm.